CD38 and plasma cell myeloma: For instance, isatuximab is known to more efficiently induce programmed cell death (PCD) of myeloma cells and to inhibit the enzymatic activity of CD38 than daratumumab, while daratumumab in contrast to isatuximab potently induces CDC (36, 41–44).